Home LiteratureArticle Details
PMID: 10319873 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Evolution of neoplastic cell lineages in Barrett oesophagus.

Nature genetics ·Vol. 22 ·No. 1 ·1999-05-00 ·Pages 106-9

Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ

Abstract

It has been hypothesized that neoplastic progression develops as a consequence of an acquired genetic instability and the subsequent evolution of clonal populations with accumulated genetic errors. Accordingly, human cancers and some premalignant lesions contain multiple genetic abnormalities not present in the normal tissues from which the neoplasms arose. Barrett oesophagus (BE) is a premalignant condition which predisposes to oesophageal adenocarcinoma (EA) that can be biopsied prospectively over time because endoscopic surveillance is recommended for early detection of cancer. In addition, oesophagectomy specimens frequently contain the premalignant epithelium from which the cancer arose. Neoplastic progression in BE is associated with alterations in TP53 (also known as p53) and CDKN2A (also known as p16) and non-random losses of heterozygosity (LOH). Aneuploid or increased 4N populations occur in more than 90-95% of EAs, arise in premalignant epithelium and predict progression. We have previously shown in small numbers of patients that disruption of TP53 and CDKN2A typically occurs before aneuploidy and cancer. Here, we determine the evolutionary relationships of non-random LOH, TP53 and CDKN2A mutations, CDKN2A CpG-island methylation and ploidy during neoplastic progression. Diploid cell progenitors with somatic genetic or epigenetic abnormalities in TP53 and CDKN2A were capable of clonal expansion, spreading to large regions of oesophageal mucosa. The subsequent evolution of neoplastic progeny frequently involved bifurcations and LOH at 5q, 13q and 18q that occurred in no obligate order relative to each other, DNA-content aneuploidy or cancer. Our results indicate that clonal evolution is more complex than predicted by linear models.

MeSH Terms
Adenocarcinoma/etiology,genetics Aneuploidy Barrett Esophagus/complications,genetics Cell Differentiation/genetics Cell Lineage/genetics Chromosome Aberrations Chromosomes, Human, Pair 13/genetics Chromosomes, Human, Pair 17/genetics Chromosomes, Human, Pair 18/genetics Chromosomes, Human, Pair 5/genetics Chromosomes, Human, Pair 9/genetics Cyclin-Dependent Kinase Inhibitor p16/genetics Disease Progression Esophageal Neoplasms/etiology,genetics Humans Loss of Heterozygosity Models, Genetic Mutation Tumor Suppressor Protein p53/genetics
Chemicals
Cyclin-Dependent Kinase Inhibitor p16 Tumor Suppressor Protein p53
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Barrett M T
Program in Cancer Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104, USA.
Sanchez C A
Prevo L J
Wong D J
Galipeau P C
Paulson T G
Rabinovitch P S
Reid B J
References (28)
28 references, click to expand
  1. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.
    Gastroenterology. 1994 Jun;106(6):1589-95 PMID: 8194706
  2. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.
    Cancer Res. 1994 May 1;54(9):2292-5 PMID: 8162566
  3. Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms.
    Oncogene. 1996 May 2;12(9):1873-8 PMID: 8649847
  4. Multiple head and neck tumors: evidence for a common clonal origin.
    Cancer Res. 1996 Jun 1;56(11):2484-7 PMID: 8653681
  5. Genetic progression model for head and neck cancer: implications for field cancerization.
    Cancer Res. 1996 Jun 1;56(11):2488-92 PMID: 8653682
  6. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus.
    Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 PMID: 8692948
  7. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma.
    Cancer Res. 1996 Oct 1;56(19):4351-3 PMID: 8813122
  8. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.
    Gut. 1996 Jul;39(1):5-8 PMID: 8881798
  9. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
    Oncogene. 1996 Nov 7;13(9):1867-73 PMID: 8934532
  10. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.
    Cancer Res. 1997 Apr 15;57(8):1597-604 PMID: 9108466
  11. Clonal genetic alterations in the lungs of current and former smokers.
    J Natl Cancer Inst. 1997 Jun 18;89(12):857-62 PMID: 9196251
  12. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
    Cancer Res. 1997 Jul 1;57(13):2619-22 PMID: 9205067
  13. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region.
    Am J Pathol. 1998 Jul;153(1):287-94 PMID: 9665490
  14. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
    Gastroenterology. 1993 Jul;105(1):40-50 PMID: 8514061
  15. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3221-5 PMID: 8475062
  16. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
    Gastroenterology. 1992 Apr;102(4 Pt 1):1212-9 PMID: 1551528
  17. Clonal expansion of p53 mutant cells is associated with brain tumour progression.
    Nature. 1992 Feb 27;355(6363):846-7 PMID: 1311419
  18. Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer.
    Gastroenterology. 1991 Nov;101(5):1198-210 PMID: 1936790
  19. Gastric precancerous process in a high risk population: cohort follow-up.
    Cancer Res. 1990 Aug 1;50(15):4737-40 PMID: 2369748
  20. A genetic model for colorectal tumorigenesis.
    Cell. 1990 Jun 1;61(5):759-67 PMID: 2188735
  21. Progression to cancer in Barrett's esophagus is associated with genomic instability.
    Lab Invest. 1989 Jan;60(1):65-71 PMID: 2911184
  22. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
    Gastroenterology. 1987 Jul;93(1):1-11 PMID: 3582897
  23. Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice?
    Ann Intern Med. 1987 Jun;106(6):902-4 PMID: 3579075
  24. Risk of colorectal cancer in adenoma-bearing individuals within a defined population.
    Int J Cancer. 1986 Aug 15;38(2):173-6 PMID: 3733258
  25. The clonal evolution of tumor cell populations.
    Science. 1976 Oct 1;194(4260):23-8 PMID: 959840
  26. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression.
    Nat Med. 1995 Sep;1(9):902-9 PMID: 7585215
  27. Molecular genetic changes found in human lung cancer and its precursor lesions.
    Cold Spring Harb Symp Quant Biol. 1994;59:565-72 PMID: 7587113
  28. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis.
    Gastroenterology. 1995 May;108(5):1361-70 PMID: 7729627
Article Info
Journal
Nature genetics
Abbr.
Nat Genet
ISSN
1061-4036
Published
1999-05-00
Pages
106-9
Language
English
Region
United States
NLM ID
9216904
PMCID
PMC1559997
Subset
IM
Grants
NCI NIH HHS · R01 CA061202 · United States
NIDDK NIH HHS · T32 DK007742 · United States
NIDDK NIH HHS · DK07742-03 · United States
NCI NIH HHS · R01CA61202 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]